Citigroup Has Lowered Expectations for Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price

Rhythm Pharmaceuticals (NASDAQ:RYTM) had its target price cut by research analysts at Citigroup from $136.00 to $131.00 in a report released on Tuesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Citigroup’s target price points to a potential upside of 52.57% from the stock’s previous close.

A number of other equities analysts have also recently weighed in on the company. TD Cowen reiterated a “buy” rating on shares of Rhythm Pharmaceuticals in a report on Thursday, December 11th. Bank of America decreased their price objective on Rhythm Pharmaceuticals from $145.00 to $139.00 and set a “buy” rating for the company in a research note on Tuesday. Stifel Nicolaus set a $131.00 price objective on shares of Rhythm Pharmaceuticals in a research report on Thursday, February 26th. Morgan Stanley reduced their price target on shares of Rhythm Pharmaceuticals from $150.00 to $136.00 and set an “overweight” rating for the company in a research report on Tuesday. Finally, Canaccord Genuity Group reduced their target price on shares of Rhythm Pharmaceuticals from $141.00 to $140.00 and set a “buy” rating for the company in a research note on Monday, March 2nd. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Rhythm Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $131.13.

Rhythm Pharmaceuticals Stock Down 2.1%

NASDAQ RYTM opened at $85.86 on Tuesday. The company has a 50 day moving average price of $99.45 and a 200 day moving average price of $102.69. Rhythm Pharmaceuticals has a 52 week low of $45.90 and a 52 week high of $122.20. The firm has a market cap of $5.86 billion, a PE ratio of -27.61 and a beta of 2.06.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last issued its quarterly earnings results on Thursday, February 26th. The company reported ($0.73) earnings per share for the quarter, topping the consensus estimate of ($0.79) by $0.06. Rhythm Pharmaceuticals had a negative net margin of 103.57% and a negative return on equity of 266.56%. The company had revenue of $57.25 million for the quarter, compared to the consensus estimate of $56.16 million. During the same quarter in the prior year, the company earned ($0.72) EPS. Rhythm Pharmaceuticals’s quarterly revenue was up 36.9% on a year-over-year basis. On average, equities research analysts anticipate that Rhythm Pharmaceuticals will post -4.32 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Rhythm Pharmaceuticals news, CAO Christopher Paul German sold 5,614 shares of the stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $89.56, for a total transaction of $502,789.84. Following the transaction, the chief accounting officer directly owned 160 shares in the company, valued at $14,329.60. This represents a 97.23% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Hunter C. Smith sold 4,385 shares of the business’s stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $101.26, for a total transaction of $444,025.10. Following the sale, the chief financial officer directly owned 110,512 shares of the company’s stock, valued at approximately $11,190,445.12. This represents a 3.82% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 27,267 shares of company stock worth $2,719,955. 6.10% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Rhythm Pharmaceuticals

A number of hedge funds have recently modified their holdings of the stock. EverSource Wealth Advisors LLC increased its position in shares of Rhythm Pharmaceuticals by 303.0% in the fourth quarter. EverSource Wealth Advisors LLC now owns 266 shares of the company’s stock worth $28,000 after acquiring an additional 200 shares in the last quarter. Smartleaf Asset Management LLC raised its holdings in shares of Rhythm Pharmaceuticals by 97.2% during the third quarter. Smartleaf Asset Management LLC now owns 286 shares of the company’s stock worth $29,000 after acquiring an additional 141 shares in the last quarter. Farther Finance Advisors LLC raised its stake in shares of Rhythm Pharmaceuticals by 1,110.3% during the 3rd quarter. Farther Finance Advisors LLC now owns 351 shares of the company’s stock worth $35,000 after purchasing an additional 322 shares in the last quarter. Optiver Holding B.V. raised its position in Rhythm Pharmaceuticals by 65.2% during the third quarter. Optiver Holding B.V. now owns 365 shares of the company’s stock valued at $37,000 after acquiring an additional 144 shares in the last quarter. Finally, SBI Securities Co. Ltd. raised its holdings in shares of Rhythm Pharmaceuticals by 73.2% during the 4th quarter. SBI Securities Co. Ltd. now owns 343 shares of the company’s stock valued at $37,000 after purchasing an additional 145 shares in the last quarter.

Key Stories Impacting Rhythm Pharmaceuticals

Here are the key news stories impacting Rhythm Pharmaceuticals this week:

• Positive Sentiment: Several major Wall Street firms lowered price targets but retained buy/overweight ratings, leaving substantial upside in consensus targets (new PTs reported in roughly the $100–$152 range). That continued analyst support may limit longer-term downdraft if management provides mitigating data or subgroup benefit. Analyst Reactions
• Positive Sentiment: A recent valuation piece argues that the stock’s pullback has improved entry valuation relative to its long-term return profile, suggesting some investors may view the decline as a buying opportunity if they believe in Rhythm’s broader franchise and pipeline. A Look At Rhythm Pharmaceuticals Valuation
• Neutral Sentiment: Rhythm released a transcript/slideshow discussing topline results and management insights from the Phase 3 EMANATE program; this provides more context but investors will need the full dataset and company guidance to reassess commercial and regulatory prospects. EMANATE Transcript & Slides
• Negative Sentiment: Multiple reports confirm Imcivree failed its late‑stage EMANATE weight‑loss trial for the targeted rare obesities, which directly increases near‑term clinical, regulatory and revenue uncertainty and was the primary driver of the share decline. Investors should watch for detailed efficacy/safety tables, any subgroup signals noted by management, and the company’s planned next steps. BioSpace: Imcivree Fails MSN: Trial Failure Coverage

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc is a clinical‐stage biotechnology company dedicated to developing targeted therapies for rare genetic diseases of obesity and metabolic dysfunction. The company’s research focuses on the melanocortin‐4 receptor (MC4R) pathway, which plays a central role in regulating appetite, energy expenditure and body weight. Using proprietary peptide technology, Rhythm aims to provide precision treatments to patients with specific genetic variants that disrupt normal weight regulation.

The company’s lead investigational product, setmelanotide, is a selective MC4R agonist designed to restore signaling in patients with deficiencies in genes such as POMC, LEPR and PCSK1.